Lineage Plasticity and Non-Genetic Resistance in Cancer

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 269 papers113 conceptsfrozen 2026-10-04

The traditional model of cancer drug resistance is a Darwinian race: a rare cell acquires a random genetic mutation that happens to protect it from a drug, allowing it to survive and eventually repopulate the tumor. However, recent evidence suggests a more sophisticated survival strategy. Instead of waiting for a lucky mutation, cancer cells can actively "shape-shift," fundamentally altering their cellular identity to bypass the pathways targeted by therapy.

This phenomenon, known as lineage plasticity, allows a tumor to survive not by fixing its "broken" genes, but by adopting an entirely different biological profile that no longer depends on those genes.

The Identity Shift as a Survival Strategy

Lineage plasticity is most visible when a tumor undergoes a radical histological transformation. In prostate cancer, for example, tumors often respond initially to androgen receptor (AR) inhibitors. However, Guanyun Wei and colleagues have shown that the RTK/RAS signaling pathway can act as a master switch, driving cells to lose their glandular identity and transition into a neuroendocrine phenotype. This "neuroendocrine transdifferentiation" creates a population of cells that simply does not require AR signaling to grow, rendering standard hormonal therapies useless.

This isn't limited to prostate cancer. Ruoxi Xiao documented cases where lung adenocarcinoma (LUAD) transformed into small cell lung cancer (SCLC) to survive targeted inhibitors. Perhaps most strikingly, Emily Robitschek and Arnav Mehta observed melanoma cells evading immunotherapy by transdifferentiating into a muscle-like cancer (rhabdomyosarcoma), effectively "hiding" from the immune system by adopting a lineage that is inherently less immunogenic.

The Epigenetic Engine of Plasticity

If the genetic blueprint (the DNA) remains the same, how do these cells change so drastically? The answer lies in the "software" of the cell: the epigenome and transcriptional programs.

Research by Tyler Risom and Ellen M. Langer in basal-like breast cancer demonstrates that targeted therapies can act as selective pressures that steer surviving cells into specific, predictable "drug-tolerant" states. These transitions are driven by epigenetic remodeling rather than new mutations. Similarly, Madonna Peter mapped the "epigenetic trajectory" of prostate cancer, showing that the shift to aggressive states involves a radical divergence in DNA methylation patterns that is distinct from other forms of resistance.

Key to this process are "pioneer" transcription factors like FOXA1 and FOXA2. As Na Liu explains, these factors physically open closed chromatin, allowing the cell to access new gene programs. When these regulators are lost or mutated, the cell's identity becomes unstable, facilitating the jump to a new lineage.

Drug-Tolerant Persisters: The Waiting Room

Before a tumor fully transforms, it often enters a state of "transcriptional noise." Nature Communications 2016 identified "Highly Variable" (HV) subpopulations that exhibit high gene expression variability. This "noise" acts as a bet-hedging strategy, allowing some cells to survive the initial "bottleneck" of treatment.

These survivors are often called Drug-Tolerant Persister (DTP) cells. Franziska Haderk and Victor Olivas identified a specific signaling axis—FAK-YAP—that allows lung cancer cells to survive initial drug exposure through non-genetic adaptations. These DTPs represent a reservoir of disease; they aren't fully resistant yet, but their plasticity gives them the time and flexibility to eventually find a permanent escape route.

The Microenvironment as an Architect of Identity

Lineage plasticity is not just an internal program; it is a conversation between the cancer cell and its surroundings. Natalie Landon-Brace and Simon Latour demonstrated that hypoxia (low oxygen) can directly drive pancreatic cancer cells from a "classical" state to a more aggressive "basal-like" subtype.

Crucially, this study found that these shifts are sometimes reversible. When oxygen levels were restored, some cells reverted to their original state. This suggests that many aggressive cancer phenotypes are not permanent genetic "locks" but transient, plastic responses to environmental stress.

Why This Matters for Therapy

The realization that resistance is often non-genetic changes how we must treat cancer. If a drug inadvertently "steers" a cell into a more aggressive lineage, then single-agent treatments may be self-defeating.

The goal is shifting toward "plasticity blockade." For example:

  • Combination Therapy: Tyler Risom showed that combining kinase inhibitors with BET inhibitors (which block epigenetic remodeling) could prevent cells from "shape-shifting" and achieve complete cell kill.
  • Timing: Manu Prasad found that certain drugs create a brief "therapeutic window" by temporarily stripping a tumor's immune shield. Timing immunotherapy to hit during this window—before the tumor can adapt—is critical.

By understanding the rules that govern how cancer cells change their identity, researchers hope to move from chasing mutations to trapping cells in states where they remain vulnerable to treatment.

Papers in this version

Showing 60 of 69 papers.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 73 papers
  2. Version 1 · 2026-10-04 · 69 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_lineage_plasticity_186c7e52,
  title = {lineage plasticity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/lineage-plasticity/rdr_186c7e52e0384699a80f06d6658bf5cb},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_lineage_plasticity_and_non_genetic_resis_186c7e52_v1,
  title = {Lineage Plasticity and Non-Genetic Resistance in Cancer},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/lineage-plasticity-and-non-genetic-resistance-in-cancer/rdr_186c7e52e0384699a80f06d6658bf5cb/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}